TVRD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tvardi Therapeutics Inc (TVRD) is not a good buy for a beginner investor with a long-term focus at this time. The stock is currently in a bearish technical trend, lacks positive catalysts, and has been downgraded by analysts with reduced price targets. Additionally, there are no recent signals from Intellectia Proprietary Trading Signals or significant insider or institutional activity to suggest immediate upside potential.
The stock is in a bearish trend with the MACD histogram below 0 and negatively contracting. RSI is neutral at 28.592, and moving averages indicate a bearish setup (SMA_200 > SMA_20 > SMA_5). The current price is below the pivot level of 2.753, with key support at 2.523 and resistance at 2.982.
No recent news or significant positive developments. The stock has a 5.32% chance of increasing in the next month based on historical candlestick patterns.
Analysts have downgraded the stock and reduced price targets due to funding concerns and delays in clinical trials. The stock's implied volatility is extremely high (999.04), indicating elevated risk. No insider or hedge fund activity suggests confidence in the stock.
No financial data available for assessment.
Barclays downgraded the stock to Underweight with a price target of $3, down from $4, citing funding overhang and delays in clinical trials. Piper Sandler also lowered the price target to $3 from $4, maintaining a Neutral rating.
